<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: Thymidylate synthase (TS) is an enzyme for DNA-synthesis and the target for <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> whereas cyclin-D1 plays a critical role in the progression of cells through the G1 phase of the cell-cycle </plain></SENT>
<SENT sid="1" pm="."><plain>There is evidence that expression of these markers may predict the outcome of patients with <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to examine the prognostic value of TS and cyclin D1 protein expression in patients with node negative <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODOLOGY: TS and cyclin D1 protein expression from 140 patients with UICC stage I and II <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was analyzed by immunhistochemistry in paraffin-embedded <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> specimens </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The 1-, 5- and 10-year overall-survival rates were 96%, 86% and 71%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> stage and recurrence were associated with overall-survival </plain></SENT>
<SENT sid="6" pm="."><plain>Low- and high TS immunoreactivity was present in 68 (48%) and 72 (52%) of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Low- and high cyclin D1 immunoreactivity was present in 98 (70%) and 42 (30%) of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Patients (n=72) with high TS expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> had a worse overall-survival than patients (n=68) with low TS expressing <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (p=0.011) </plain></SENT>
<SENT sid="9" pm="."><plain>No difference in overall-survival was seen between patients with high and low cyclin D1 expressing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: TS may be helpful as a prognostic marker in lymph node negative <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>